Denali Therapeutics (DNLI) Short term Debt (2022)

Denali Therapeutics' (DNLI) quarterly Short term Debt came in at $4.4 million in Q4 2022, up 204.09% on a QoQ basis from $1.4 million in Q3 2022.

Denali Therapeutics (DNLI) Short term Debt (2022) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Short term Debt data on file, last reported at $4.4 million in Q4 2022.

On a quarterly basis, Short term Debt changed N/A year-over-year to $4.4 million in Q4 2022; TTM through Dec 2022 was $4.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $4.4 million, changed N/A from the prior year.
Short term Debt for Q4 2022 stood at $4.4 million, up from $1.4 million in the prior quarter.
Over the last five years, Short term Debt for DNLI reached as high as $4.4 million in Q4 2022 and fell as low as $1.4 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Denali Therapeutics	4.37 Bn	4.37 Bn	-

Download Data